ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO046

An Atypical Case of DNAJB9 Negative Fibrillary Glomerulonephritis Associated With COVID-19 Infection

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Shehzad, Pir, Baystate Medical Center, Springfield, Massachusetts, United States
  • Khan, Sabiha M., Baystate Medical Center, Springfield, Massachusetts, United States
  • Hodgins, Spencer, Baystate Medical Center, Springfield, Massachusetts, United States
  • Freeman, Jonathan, Baystate Medical Center, Springfield, Massachusetts, United States
  • Braden, Gregory Lee, Baystate Medical Center, Springfield, Massachusetts, United States

FGN is a rare immune-complex mediated GN characterized by the demonstration of Congo-red negative, randomly organized nonbranching fibrils with a diameter of 15 nm - 25 nm on electron microscopy and more recently the presence of DNAJB9 protein in almost all patients. FGN has been associated with HCV infection, autoimmune disease, malignancy, and monoclonal gammopathies. We report a unique case of DNAJB9 negative FGN associated with COVID-19 Infection.

Case Description

74 yo M with Afib, HTN, HFrEF, and DM presented with fatigue and dizziness. Labs revealed an elevated serum creatinine of 1.0 mg/dL above the baseline of 0.7 mg/dL. The patient was positive for COVID-19 infection without overt symptoms. The patient had been vaccinated against SARS-CoV-2. The patient developed oliguric AKI with a rapid rise in serum creatinine over 4 days. Urinalysis revealed pyuria, hematuria, and 4+ albuminuria with 14 gm of proteinuria on quantification (TP/Cr). He had hypocomplementemia, normal immunofixation, negative ANA, dsDNA, RF, ANCA, anti-GBM antibody, viral hepatitis antibodies, and cryoglobulin. MRA ruled out renal vein thrombosis. The patient was started on 1g methylprednisolone for three days. His creatinine peaked at 9.9 mg/dL and was started on hemodialysis. A kidney biopsy was done. Light microscopy showed DPGN with IF demonstrating a full house pattern most consistent with Class IV Lupus Nephritis. The Congo-red stain was negative. Electron microscopy was delayed. He was started on Euro-lupus protocol with IV Cytoxan, 500 mg IV every 2 weeks for 6 weeks, and Prednisone. The patient was discharged on maintenance Euro-lupus protocol and had an excellent response to therapy with normalization of serum creatinine to his baseline of 0.7 mg/dL and a decrease in proteinuria (TP/Cr of 0.47). The electron microscopy results later showed non-branching randomly arranged fibrils with thickness ranging from 15 nm - 30 nm characteristic of FGN. Testing for DNAJB9 was negative.


DNAJB9 has been identified in all but a few cases of FGN. There is currently no known association between COVID-19 infection and FGN. Our case is unique since it's DNAJB9 negative and potentially establishes a new association between FGN and COVID-19 infection which can cause AKI reversible upon IV Cytoxan therapy usually reserved for crescentic FGN.